Intra-operative pubic arch interference during prostate seed brachytherapy in patients with CT-based pubic arch interference of ≤1 cm

Radiotherapy and Oncology

Volumn 91, Issue 2, 2009, Pages 249-254

  Sejpal, Samir V ^a   Sathiaseelan, Vythialingam ^a   Helenowski, Irene B ^a   Kozlowski, James M ^a   Carter, Michael F ^a   Nadler, Robert B ^a   Dalton, Daniel P ^a   McVary, Kevin T ^a   Lin, William W ^a   Garnett, John E ^a   Kalapurakal, John A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Brachytherapy; Dosimetry; Prostate cancer; Pubic arch interference; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGED; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; INTRAOPERATIVE PUBIC ARCH INTERFERENCE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PUBIC BONE;

AGED; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PUBIC BONE; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65449119117     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.02.006     Document Type: Article

References (28)

1. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
2. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
3. 90 and outcome for I-125 seed implant monotherapy for localized prostate cancer. Radiother Oncol 79 (2006) 185-189
4. Ash D., Bottomley D., Al-Qaisieh B., et al. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localized prostate cancer. Radiother Oncol 84 (2007) 135-139
5. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
6. Battermann J.J., Boon T.A., and Moerland M.A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71 (2004) 23-28
7. Bellon J., Wallner K., Ellis W., et al. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 43 (1999) 579-581
8. Wallner K., Ellis W., Russell K., et al. Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int J Radiat Oncol Biol Phys 43 (1999) 558-585
9. Tincher S.A., Kim R.Y., Ezkiel M.P., et al. Effects of pelvic rotation and needle angle on pubic arch interference during transperineal prostate implants. Int J Radiat Oncol Biol Phys 47 (2000) 361-363
10. Strang J.G., Rubens D.J., Brasacchio R.A., et al. Real-time US versus CT determination of pubic arch interference for brachytherapy. Radiology 219 (2001) 387-393
11. Wallner K., Chiu-Tsao S.T., Roy J., et al. An improved method for computerized tomography-planned transperineal I-125 prostate implants. J Urol 146 (1991) 90-95
12. Peschel R.E., King C.R., and Roberts K. Pubic arch interference in permanent prostate implant patients. J Brachytherapy Int 14 (1998) 241-248
13. Prestidge B.R., Prete J.J., Buchholz T.A., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40 (1998) 461-465
14. Kalapurakal J.A., Raman N.V., St. John K., et al. Correlation of pre-implant computed tomography pubic arch study with postimplant dosimetry. J Brachytherapy Int 15 (1999) 217-221
15. Grimm P., Blasko J., and Sylvester J. Clinical selection issues for permanent seed prostate brachytherapy. J Brachytherapy Int 17 (2001) 143-152
16. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No 43. Med Phys 22 (1995) 209-234
17. Roach M., Marquez C., You H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
18. The National Heart, Lung and Blood Institute Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. J Am Diet Assoc 1998;98:1177-91.
19. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 65 (2005) 95-100
20. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
21. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
22. Nag S., Ciezki J.P., Cormack R., et al. Intra-operative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 51 (2001) 1422-1430
23. Nag S., Shi P., Liu B., et al. Comparison of real-time intra-operative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy. Int J Radiat Oncol Biol Phys 70 (2008) 311-317
24. Pathak S.D., Grimm P.D., Chalana V., et al. Pubic arch detection in transrectal ultrasound guided prostate cancer therapy. IEEE Trans Med Imaging 17 (1998) 762-771
25. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
26. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
27. Strom S.S., Kamat A.M., Gruschkus S.K., et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107 (2006) 631-639
28. Merrick G.S., Rockhill J., Wallner K., Hoffman C., et al. Prostate brachytherapy in obese patients. Brachytherapy 1 (2002) 54-60